An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a New Influenza A H3N2 Challenge Strain in Healthy Participants 18 to 55 Years of Age In Part A, up to 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2). Based on the outcome of Part A, participants in Part B, may be given Virus Dose 1, Virus Dose 2, or another virus dose (e.g., Virus Dose 3)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Occurrence of Adverse Events Related to the Viral Challenge
Timeframe: Day 0 to Day 28
Occurrence of Serious Adverse Events Related to the Viral Challenge
Timeframe: Day 0 to Day 28
Induces Laboratory-confirmed Infection in ≥40% of Inoculated Participants
Timeframe: Day 1 to Day 8